13
Participants
Start Date
June 21, 2017
Primary Completion Date
July 16, 2024
Study Completion Date
July 16, 2024
SB-525 (PF-07055480)
Single dose of investigational product SB-525 (PF-07055480)
Hemophilia Center of Western PA, Pittsburgh
UPMC Montefiore Clinical and Translational Research Center, Pittsburgh
UPMC, Investigational Drug Service, Pittsburgh
Emory University School of Medicine, Atlanta
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami
USF Health Morsani Center For Advanced Healthcare, Tampa
Vanderbilt Hemostasis Treatment Clinic, Nashville
Vanderbilt Hemostasis-Thrombosis Clinic, Nashville
Arkansas Children's Hospital, Little Rock
City of Hope Medical Center, Duarte
University of California, San Francisco - Outpatient Hematology Clinic, San Francisco
University of California, San Francisco -Moffitt Hospital, San Francisco
Midtown Ambulatory Care Center, Sacramento
UC Davis Ambulatory Care Clinic, Sacramento
UC Davis Comprehensive Cancer Center, Sacramento
UC Davis CTSC Clinical Research Center, Sacramento
UC Davis Hemophilia Treatment Center, Sacramento
UC Davis Investigational Drug Services Pharmacy, Sacramento
UC Davis Medical Center, Sacramento
Washington Institute for Coagulation, Seattle
University of California, San Francisco - Investigational Drug Service (IDS) Pharmacy, San Francisco
Vanderbilt University Medical Center Clinical Research Center, Nashville
Lead Sponsor
Pfizer
INDUSTRY